To me, a company fighting to 'make it/survive' and get some 'revenues
flowing? Has every right to do what they need to in order to
succeed. And doesn't owe us 'retail' shareholders anything
especially if its not in the best interest of the companys success.
There is another board UMAV where things are happening, that
the CEO has indicated he wanted to accomplish (their agenda).
Folks are upset tho that he seems to 'not care' about the shareholders.
As I said over there, the company owes us nothing. For in my opinion,
our only contribution to the equation is that we are committing our $s
hoping to get more down the road..
So as far as 'not being shareholder friendly? My closing comment is,
IF we timed our buys right, if our analysis of the potential is conservative
and turns out to be correct? We stand a chance of coming out ahead.
And yeah, I know this will not be a popular position.
But it puts all of the 'burden' on the odds of my success on me getting it 'right'
when it comes again, to my analysis of whats going on and the timing of when
I decide to buy.
From this point forward? And until they advance something
else that WORKS (passes its trial), to me, what happens
is all going to be dependent on the sales and growth of.
I am anticipating that given how reportedly 'bad' it is for folks
dealing with the fibro disease, that reportedly NEED something
to help them. That folks will at least try it. And IF it helps, will use it
till it no longer does.
And why I am keeping an eye on the institutional holding and if we can uncover it,
which institutional folks are taking a position.
This all said, I suspect that until they can report some 'sales/script' numbers, its
possible it doesn't do too much.
And IF they succeed in seeing increasing sales/revenues? Then its possible
they pull something off like a forward split. Which in reality is about all they can
do to help shareholders out (besides stop diluting) at this stage of their corporate
development.
AI
Market Data 
Markets 
